Unstable angina / non ST elevation myocardial infarction anticoagulant therapy

Intern Survival Guide

Unstable angina / NSTEMI Microchapters
Home
Patient Information
Overview
Classification
Pathophysiology
Unstable Angina
Non-ST Elevation Myocardial Infarction
Differentiating Unstable Angina/Non-ST Elevation Myocardial Infarction from other Disorders
Epidemiology and Demographics
Risk Stratification
Natural History, Complications and Prognosis
Special Groups
Women
Diabetic Patients
Post CABG Patients
Elderly
Chronic Kidney Disease
Substance Abusers
Prinzmetal's Angina
Cardiovascular Syndrome X
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Blood Studies
Biomarkers
Electrocardiogram
Chest X Ray
Echocardiography
Coronary Angiography
Treatment
Primary Prevention
Immediate Management
Antithrombin Therapy
Antitplatelet Agents
Antiplatelet therapy recommendations
Aspirin
Thienopyridines
Glycoprotein IIb/IIIa Inhibitor
Additional Management Considerations for Antiplatelet and Anticoagulant Therapy
Mechanical Reperfusion
Initial Conservative Versus Initial Invasive Strategies
PCI
CABG
Complications of Bleeding and Transfusion
Discharge Care
Medical Regimen
Post-Discharge Follow-Up
Cardiac Rehabilitation
Long-Term Medical Therapy and Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Unstable angina / non ST elevation myocardial infarction anticoagulant therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Unstable angina / non ST elevation myocardial infarction anticoagulant therapy
CDC onUnstable angina / non ST elevation myocardial infarction anticoagulant therapy
Unstable angina / non ST elevation myocardial infarction anticoagulant therapy in the news
Blogs on Unstable angina / non ST elevation myocardial infarction anticoagulant therapy
to Hospitals Treating Unstable angina / non ST elevation myocardial infarction anticoagulant therapy
Risk calculators and risk factors for Unstable angina / non ST elevation myocardial infarction anticoagulant therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-in-Chief: Varun Kumar, M.B.B.S.; Lakshmi Gopalakrishnan, M.B.B.S.; Smita Kohli, M.D.

Overview

Anticoagulation, traditionally with unfractionated heparin (UFH), is a cornerstone of therapy for patients with unstable angina]]/[[NSTEMI. Some of the agents available in this category include unfractionated heparin, low molecular weight heparin, direct thrombin inhibitors (e.g., bivalirudin) factor Xa Inhibitors (e.g., fondaparinux), and warfarin. These agents are also sometimes referred to as antithrombins, although, it should be noted that they often inhibit one or more proteins in the coagulation cascade before thrombin.

Anticoagulant Therapy in UA/NSTEMI

You can read in greater detail about each of the therapies specifically in relation to unstable angina and NSTEMI, by clicking on the link for that therapy:

• Unfractionated heparin
• Low molecular weight heparin
• Direct thrombin inhibitors
• Factor Xa inhibitors
• Long-term anticoagulation

2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non -ST-Elevation Myocardial Infarction (DO NOT EDIT)

Anticoagulant Therapy (DO NOT EDIT)

Class I

"1. Anticoagulant therapy should be added to antiplatelet therapy in UA / NSTEMI patients as soon as possible after presentation.

a) For patients in whom an invasive strategy is selected, regimens with established efficacy at a (Level of Evidence: A) include enoxaparin and UFH, and those with established efficacy at a (Level of Evidence: B) include bivalirudin and fondaparinux.

b) For patients in whom a conservative strategy is selected, regimens using either enoxaparin‡ or UFH (Level of Evidence: A) or fondaparinux (Level of Evidence: B) have established efficacy. See also Class IIa recommendation below.

c) In patients in whom a conservative strategy is selected and who have an increased risk of bleeding, fondaparinux is preferable. (Level of Evidence: B)"

Class IIa

"1. For UA / NSTEMI patients in whom an initial conservative strategy is selected, enoxaparin‡ or fondaparinux is preferable to UFH as anticoagulant therapy, unless CABG is planned within 24 h. (Level of Evidence: B)"

“

‡ Limited data are available for the use of other LMWHs (e.g., dalteparin) in UA/NSTEMI.

”